Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation Combined With Anlotinib Plus TQB2868 in Advanced Intrahepatic Cholangiocarcinoma
NCT07846267Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, TQB2868 in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
anlotinibTQB2868
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07846267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846267.